[The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa (author's transl)].
Patients with hyperlipoproteinemia, type IIa, were treated with an adequate diet; additionally they were given 500 mg etofibrate daily. Within 14 days the total cholesterol-level in serum, LDL and LDL-cholesterol were reduced significantly, whereas the level of HDL was not affected. The potency of etofibrate is equal to approximately 50 to 80% of the lipid-lowering effect of clofibrate in an optimal dosis of 2 g/day.
D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D000924:Anticholesteremic Agents; D003692:Delayed-Action Preparations; C009746:etofibrate; D002995:Clofibric Acid; D002994:Clofibrate
Zur Wirkung von Etofibrat-retard bei Hyperlipoproteinämie Typ IIa.